Thursday, October 22, 2015

WELCOME and OPENING (8:30-9:00) Alain Weill and Alain Baumann

SAFETY, SUPPLY AND ACCESS TO TREATMENT PRODUCTS

Chair: William Murphy
Blood safety and availability – current and emerging issues (9:00-9:30)
Albert Farrugia

Impact of MSM donor deferrals on safety and supply (9:30-10:00)
William Murphy (Irish Blood Transfusion Service)

BREAK (10:00-10:30)

Chair: Marijke van den Berg
Inhibitor development: update on surveillance data and analysis (10:30-11:30)
Anneliese Hilger: Report on the EMA workshop on hemophilia registries
Mike Soucie: Surveillance for inhibitors in the US
Glenn Pierce: Report on FDA inhibitor workshop

EMA guidelines on transparency for clinical trials (11:30-12:00)
Marijke van den Berg

LUNCH (12:00-1:00)

Chair: Brian O’Mahony
Barriers to access in the developing world (1:00-1:30)
Albert Farrugia

The changing economics of blood collection (1:30-2:00)
Kathleen Rowe

Tender & procurement – challenges and opportunities (2:00-2:30)
Brian O’Mahony

BREAK (2:30-3:00)
Expansion of the WFH Humanitarian Aid program (3:00-3:30)
Assad Haffar

How to measure progress in the provision of care for hemophilia (3:30-4:00)
Alfonso Iorio

Inclusion of DDAVP on WHO Essential Medicines List and implications for access (4:00-4:30)
Mark Brooker

Outcomes of low-dose prophylaxis in children (4:30-5:00)
Magdy El Ekiaby

RECEPTION (6:00-8:00)

Friday, October 23, 2015

RESEARCH

Chair: David Lillicrap
Novel developments in treatment of bleeding disorders (8:30-9:30)
Midori Shima: Factor VIII mimetics
Gary Gilbert: Non-factor replacement strategies: anti-coagulant inhibition
Manuel Carcao: Prolonged-half life products; current clinical practices

Gene therapy update (9:30-10:00)
Edward Tuddenham

Gene therapy for hemophilia – future scenarios for cost, capacity, and impact on FVIII therapy (10:00-10:30) Mark Skinner, Glenn Pierce

BREAK (10:30-11:00)

Chair: Magdy El Ekiaby
WFH Research program: outcomes and future directions – panel discussion (11:00-11:30)
Panel discussion chaired by David Lillicrap.

WFH epidemiological research program (11:30-12:00)
Alok Srivastava

LUNCH (12:00-1:00)
Updates from WFH clinical research grant recipients (1:00-1:30)

Sébastien Lobet: Quantifying foot biomechanics in hemophilic children
Lize van Vulpen: Joint distraction in the treatment of hemophilic ankle arthropathy

MANUFACTURERS UPDATES 1:30-5:00

Chair: Alok Srivastava

Rare factor products, the product pipeline, future novel therapies and alternative routes of administration

- **Sobi/Biogen**: Geoff McDonough
  Fc-fusion haemophilia products - potential to advance the standard of care
- **Kedrion Biopharma**: Garrett Bergman
  Kedrion grows as a Global Company
- **Grifols**: Juan Jorquera
  The natural protection of FVIII by VWF against inhibitors
- **Bio Products Laboratory**: Eric Wolford
  Pharmacokoenetics, safety, and efficacy of Coagadex®, a new high-purity factor X concentrate in patients with heredity factor X deficiency
- **Baxalta**: Anne Prener
  Meeting unmet needs in hematological disorders

BREAK (2:30-3:00)

- **Bayer**: Nikolaus Mueller
  Bayer’s Commitment to the Hemophilia Community: The Future of Hemophilia A Care
- **Pfizer**: Marcus Carr
  Pfizer Update on Hematology Pipeline
- **Novo Nordisk**: Karin Knobe
  N8-GP & N9-GP Update
- **Octapharma**: Sylvia Werner
  Emerging data from ongoing global studies with Nuwiq®
- **CSL Behring**: Debra Bensen-Kennedy
  Outcomes of pivotal studies for rVIII-SingleChain and rIX-FP and a new research program for rVIIa-FP

CLOSE OF MEETING (5:00)